Cancer, the second leading cause of death globally according to the World Health Organisation, is responsible for an estimated 9.6 million deaths in 2018.
In light of projections that the cancer incidents in Europe will double by 2035, a new survey conducted by Central and Eastern European Cancer Action Group (CEECAG), has identified large differences between Europe’s west and central and eastern countries in handling cancer.
In her mission letter to the proposed new EU Health Commissioner Stella Kyriakides, the President-elect of the EU executive, Ursula von der Leyen, said an EU-wide “Beating Cancer” plan should be put forward in order to help member states improve cancer prevention and care.
“This should propose actions to strengthen our approach at every key stage of the disease: prevention, diagnosis, treatment, life as a cancer survivor and palliative care. There should be a close link with the research mission on cancer in the future Horizon Europe programme,” von der Leyen wrote.
A new survey conducted by the Central and Eastern European Cancer Action Group (CEECAG) has found severe shortcomings in managing cancer incidents in Central and Eastern Europe (CEE), whose “young brains” increasingly move to the west.
The governments should take full responsibility for the implementation of national cancer plans, which are a commitment toward people and not just a piece of paper, health expert Dr Tit Albreht told EURACTIV.com in an interview.
Medical experts and stakeholders from patient advocacy groups are keen to point out how crucial it is to consider patients’ voice as an added value when conducting cancer clinical trials, whatever policy on cancer, national or EU-wide, will eventually be put together.
The European People’s Party (EPP), the biggest political group in the EU assembly, will ask for the creation of a special parliamentary committee to help formulate a new EU-wide plan to combat cancer. EURACTIV.com and EURACTIV.cz report from Strasbourg.
Having a pan-European cancer control plan is crucial, but some flexibility should be granted to member states in choosing which aspect to prioritise within the framework, said Linda Gibbs from Pfizer Oncology in an interview with EURACTIV.com.
Despite encouraging advances in science and technology, cancer rates continue to rise across the world. The International Agency for Research on Cancer (IARC) estimates that one-in-five men and one-in-six women worldwide will develop cancer over the course of their lifetime, …